Press Releases
PatientSight announces the launch of the Patient Experience Benchmark Report. | PharmaVoice
PatientSight announced the launch of the Patient Experience Benchmark Report (PEBR), which is based on primary research with patients affected by rare and complex diseases, converting qualitative journey insights into comparable quantitative metrics to support performance evaluation and improvement across patient populations and therapeutic areas. The report is available in both customized and syndicated formats, accompanied by executive presentations or an interactive platform with AI query capabilities.
Medical Communications Teams Spend Months Building Scientific Narratives. MEDSTORY•AI® Delivers a Defensible First Draft in 90 Minutes. | PharmaVoice
Medical communication teams have long struggled with multiple review rounds and high costs. SBC's MEDSTORY•AI, through its proprietary story angle library and core story concepts, delivers three complete citation-output drafts in 90 minutes, drastically shortening the traditional 1-to-4-month delivery cycle.
Cresset releases Flare V12 to cut synthesis and testing cycles with faster, more flexible FEP | PharmaVoice
Cresset releases Flare V12, aimed at accelerating compound screening and decision-making in drug discovery through faster, more flexible FEP technology that lowers computational costs and supports complex chemical transformations.
Kairos Meridian Launches An Independent, Shorter Path From Problem to Impact | PharmaVoice
Kairos Meridian was officially established on June 30, 2026, in Millstone Township, New Jersey, USA, as an independent life sciences commercial consulting firm specializing in marketing, data, analytics, omnichannel, and innovation. It aims to help pharmaceutical and life sciences commercial teams find clear direction and achieve measurable impact in an environment where data, channels, and AI tools are increasingly abundant but focus is blurred.
Methyl-Life® Introduces New Folinic Acid Formula to Expand Folate Support Options | PharmaVoice
Methyl-Life® launched a new folate supplement in July 2026, with each tablet containing 1.6 mg of calcium folinate (a form of folate), providing a new option for those needing non-methylated folate. The product is third-party tested, meets cGMP standards, and is free from common allergens.
Inizio Launches Connected Insights to Transform Global Medical Information | PharmaVoice
On July 28, 2026, Inizio announced the launch of Connected Insights through Inizio Engage, aimed at helping pharmaceutical and biotechnology companies turn medical information into strategic intelligence. This investment expands specialized capabilities in the Asia-Pacific region, global infrastructure, and AI functions, supporting over one million medical information interactions annually, 500+ products, 20+ languages, and significantly improving training efficiency.
Receptor.AI and Sethera Therapeutics Partner to Build an End-to-End DMTA Cycle for Polymacrocyclic Peptide Medicines | PharmaVoice
Receptor.AI and Sethera Therapeutics announced a strategic collaboration on August 5, 2026, aimed at building an end-to-end design-make-test-analyze (DMTA) cycle for macrocyclic peptide drugs. The collaboration will combine Sethera's enzymatic platform with Receptor.AI's computational capabilities to advance lead optimization against difficult-to-drug targets.
Veloxis Insiders Knew Better: Yet Only One Came Forward | PharmaVoice
Veloxis has agreed to pay more than $46 million to resolve criminal and civil charges arising from its promotion of the kidney transplant immunosuppressant Envarsus XR through sham consulting arrangements, improper pharmacy payments, and lavish entertainment. The settlement includes approximately $10.04 million in criminal fines, a three-year deferred prosecution agreement, a $34.45 million civil settlement, and a $1.55 million Sunshine Act penalty. Whistleblower attorneys noted that insiders discovered the truth before the government, but only one proactively reported it.
Saw.com Lists GLP1.com for Sale, the Exact-Match Domain for a $200 Billion Healthcare Category | PharmaVoice
Saw.com has listed GLP1.com for sale, a scarce .COM domain that precisely matches the entire GLP-1 healthcare category. J.P. Morgan predicts the related market will reach approximately $200 billion by 2030, when 25 to 30 million Americans may receive treatment. The domain is category-neutral, helping holders establish brand leadership in the rapidly growing healthcare sector.
Galen and POA Pharma unveil Galsana, a new global brand for rare metabolic diseases | PharmaVoice
Galen Ltd and POA Pharma announced the launch of Galsana at the SSIEM Annual Symposium in Helsinki as a new global brand for their metabolic portfolio, integrating existing products, professional support, and services to serve patients with rare metabolic diseases under a unified identity.